Genentech signs $1bn-plus DualityBio deal to develop next-generation ADCs
Genentech has entered a global collaboration with DualityBio to develop antibody-drug conjugates using novel payloads designed to address tumors resistant to widely used topoisomerase inhibitor ADCs.